Open AccessCancer immunotherapy‐targeted glypican‐3 or neoantigens
Author(s) -
Shimizu Yasuhiro,
Suzuki Toshihiro,
Yoshikawa Toshiaki,
Tsuchiya Nobuhiro,
Sawada Yu,
Endo Itaru,
Nakatsura Tetsuya
Publication year - 2018
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13485
Subject(s) - medicine , immunotherapy , cancer , clinical trial , cancer immunotherapy , oncology , immunology
Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican‐3 an HLA ‐24, HLA ‐A2 restriction peptide with extreme cancer specificity. In this paper, we summarize results from a number of related clinical trials showing that glypican‐3 peptide vaccines induce specific CTL s in most patients ( UMIN Clinical Trials Registry: UMIN 1395, UMIN 5093, UMIN 2614, UMN 3696, and UMIN 6357). We also describe the current state of personalized cancer immunotherapy based on neoantigens, and assess, based on our own research and experience, the potential of such therapy to elicit cancer regression. Finally, we discuss the future direction of cancer immunotherapy.